NCT03000530View on ClinicalTrials.gov

A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

December 7, 2016

Primary Completion Date

October 4, 2017

Study Completion Date

November 8, 2017

Conditions
Major Depression
Interventions
DRUG

SAGE-217

DRUG

Placebo

Trial Locations (8)

22908

Sage Investigational Site, Charlottesville

30331

Sage Investigational Site, Atlanta

32806

Sage Investigational Site, Orlando

45417

Sage Investigational Site, Dayton

70629

Sage Investigational Site, Lake Charles

78754

Sage Investigational Site, Austin

92845

Sage Investigational Site, Garden Grove

08009

Sage Investigational Site, Berlin

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY